Capricor Therapeutics (NASDAQ:CAPR) 报告2024年第四季度每股亏损 $(0.16)，优于分析师一致预期的 $(0.26)，超出预期38.46%。这一结果较去年同期每股亏损 $(0.02) 增加了700%。此外，公司报告季度销售额为 $11.10M，优于分析师一致预期的 $5.68M，超出预期95.37%。但与去年同期的销售额 $12.09M 相比，下降了8.17%。

以上内容来自Benzinga Earnings专栏，原文如下：

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 38.46 percent. This is a 700 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $11.10 million which beat the analyst consensus estimate of $5.68 million by 95.37 percent. This is a 8.17 percent decrease over sales of $12.09 million the same period last year.